Please login to the form below

Not currently logged in
Email:
Password:

GSK's Duodart receives approval in Europe

GlaxoSmithKline's (GSK) two-in-one prostate drug Duodart has received approval in Europe

GlaxoSmithKline's (GSK) two-in-one prostate drug Duodart has received approval in Europe. Duodart is the first fixed dose combination for prostate enlargement or benign prostatic hyperplasia (BPH) — an increasingly common problem for men as they age.

European approval was given via the Decentralised Procedure, with Germany acting as Reference Member State. The decision came 10 days after the drug received the green light in Switzerland, its first European market.

Duodart combines GSK's established drug Avodart (dutasteride) with Astellas Pharma's off-patent product Flomax (tamsulosin). In a four-year study the combination therapy was found to be more effective than monotherapy in improving symptoms and clinical outcomes in men with moderate-to-severe symptomatic BPH.

Said Eddie Gray, president, Pharmaceuticals Europe, GSK: "Recognising the benefits of these two medicines and the significant proven benefit of their dual use, GSK developed this new fixed dose combination medicine to provide patients and physicians with a convenient, once-daily treatment, which reduces the impact of the bothersome symptoms of this common condition, and the risk of potential complications and related surgery. These are the factors which create uncertainty and anxiety for many men and may also lead to additional unplanned costs for healthcare providers."

31st March 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....